Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Raymond Moses: Unleashing the Financial Potential of Billions!
Transgene Biotek is currently trading at Rs. 11.75, up by 0.15 points or 1.29% from its previous closing of Rs. 11.60 on the BSE.
The scrip opened at Rs. 11.70 and has touched a high and low of Rs. 12.15 and Rs. 11.40 respectively. So far 6,45,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 62.50 on 16-Nov-2011 and a 52 week low of Rs. 10.55 on 20-Jul-2012.
Last one week high and low of the scrip stood at Rs. 14.70 and Rs. 10.55 respectively. The current market cap of the company is Rs. 77.00 crore.
The promoters holding in the company stood at 9.71% while Non-Institutions hold 52.28% respectively.
Transgene Biotek’s patented oral insulin TrabOrlin has once again proven the efficacy and high bio-availability in yet another extensive randomized single blinded study conducted at a reputed CRO facility on a large number of animals. This data reconfirms the exciting results reported earlier from another study center. This is a significant milestone in the development of oral insulin by the company, which embarked on this project nearly 10 years ago overcoming several technology challenges.
This milestone not only accelerates project development towards the next stage but also provides an opportunity to seek strategic deals with pharma majors and other in-licensing partners. Besides, these exciting results of TrabOrlin’s coincide with the sale of DHA (approximately 5 tonne per year) from one customer alone and the company has already started delivering the consignments. The company is expecting to receive several other orders to follow in the coming days.
It is probably the only company in India that produces and supplies vegetable (Algal) sourced DHA in both oil and powder form. The above two progressive strides by the company are in addition to the other oncology and auto-immune projects advancing as per the schedules. Transgene Biotek is a biotechnology company. It is involved in the development of several cutting edge technologies.
| Company Name | CMP |
|---|---|
| Apollo Hospital Ent. | 7036.65 |
| Max Healthcare Inst | 1006.75 |
| Narayana Hrudayalay | 1249.35 |
| Aster DM Healthcare | 444.55 |
| Global Health | 1115.50 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
